×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:CRSP

CRISPR Therapeutics Price Target, Predictions & Analyst Ratings

$66.96
+1.81 (+2.78%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$61.06
$67.16
50-Day Range
$43.23
$73.83
52-Week Range
$42.51
$169.76
Volume
2.95 million shs
Average Volume
1.70 million shs
Market Capitalization
$5.19 billion
P/E Ratio
18.55
Dividend Yield
N/A
Price Target
$111.40

CRISPR Therapeutics (NASDAQ:CRSP) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 16 Analyst Ratings

Consensus Analyst Price Target

$111.40
66.37% Upside
High Price Target$220.00
Average Price Target$111.40
Low Price Target$46.00
TypeCurrent
6/24/21 to 6/24/22
1 Month Ago
5/25/21 to 5/25/22
3 Months Ago
3/26/21 to 3/26/22
1 Year Ago
6/24/20 to 6/24/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
13 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$111.40$114.71$129.83$159.69
Predicted Upside66.37% Upside87.68% Upside73.72% Upside21.41% Upside
Get CRISPR Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.


CRSP Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CRSP Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CRISPR Therapeutics Stock vs. The Competition

TypeCRISPR TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.63
2.71
2.52
Consensus RatingModerate BuyBuyBuy
Predicted Upside70.70% Upside436.47% Upside30.55% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
423
68.56%
Underperform Votes
194
31.44%
Avg. Outperform Votes
171
67.06%
Avg. Underperform Votes
84
32.94%
Avg. Outperform Votes
840
69.14%
Avg. Underperform Votes
375
30.86%

Historical CRISPR Therapeutics Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/23/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$150.00 ➝ $122.00+103.54%
6/22/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$168.00 ➝ $164.00+153.60%
6/22/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$115.00 ➝ $121.00+87.10%
6/16/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$98.00+51.59%
6/13/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$52.00 ➝ $57.00-10.60%
5/24/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$52.00 ➝ $46.00-12.93%
5/17/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$64.00 ➝ $53.00+2.83%
5/13/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$170.00 ➝ $122.00+132.78%
5/10/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$95.00 ➝ $85.00+96.62%
5/10/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$107.00 ➝ $99.00+129.01%
4/28/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$78.00+50.12%
2/16/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joon Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$220.00+262.20%
2/16/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Bienkowski
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$126.00 ➝ $120.00+96.82%
2/14/2022Brookline Capital Acquisition
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$143.00+137.58%
2/14/2022Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Leah Rush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$143.00+140.74%
12/6/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
10/13/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
5/13/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeOutperform
4/21/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$172.00+41.37%
3/4/2021JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$160.00+34.36%
12/7/2020Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$115.00 ➝ $170.00+15.22%
12/7/2020Wells Fargo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$102.63 ➝ $145.00-1.72%
10/30/2020Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell
10/5/2020Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$110.00 ➝ $110.00+38.07%
7/14/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$140.00+62.36%
12/16/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Edward Tenthoff
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$104.00+56.79%
7/30/2019BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Positive$51.00 ➝ $59.00+14.96%
(Data available from 6/24/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CRISPR Therapeutics Price Target - Frequently Asked Questions

What is CRISPR Therapeutics's consensus rating and price target?

According to the issued ratings of 16 analysts in the last year, the consensus rating for CRISPR Therapeutics stock is Moderate Buy based on the current 6 hold ratings and 10 buy ratings for CRSP. The average twelve-month price prediction for CRISPR Therapeutics is $111.40 with a high price target of $220.00 and a low price target of $46.00. Learn more on CRSP's analyst rating history.

Do Wall Street analysts like CRISPR Therapeutics more than its competitors?

Analysts like CRISPR Therapeutics stock less than the stock of other Medical companies. The consensus rating for CRISPR Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how CRSP compares to other companies.

Do MarketBeat users like CRISPR Therapeutics more than its competitors?

MarketBeat users like CRISPR Therapeutics stock more than the stock of other Medical companies. 68.56% of MarketBeat users gave CRISPR Therapeutics an outperform vote while medical companies recieve an average of 66.93% outperform votes by MarketBeat users.

Does CRISPR Therapeutics's stock price have much upside?

According to analysts, CRISPR Therapeutics's stock has a predicted upside of 82.92% based on their 12-month price targets.

What analysts cover CRISPR Therapeutics?
This page (NASDAQ:CRSP) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.